Cytori Therapeutics

Das war sonst nicht der Fall.  

TOKYO, May 16, 2008 (BUSINESS WIRE) -- Early results were reported from an independent study in Japan using adipose-derived stem and regenerative cells for breast augmentation. Early results on the first three patients from this investigator-initiated study showed the increase in breast volume was maintained at three months and that the tissue remained soft and natural. The findings were reported earlier this week by the investigator, Tatsuro Kamakura, M.D., Chief Medical Officer of Cosmetic Surgery Seishin, at the 94th Bi-Annual Congress of the Japan Society of Aesthetic Surgery (www.biyou-clinic.jp/jsas/).

"Volume retention and softness of tissue at three-months is extremely encouraging compared to typical outcomes in non-cell-enhanced fat transfers," said Dr. Kamakura. "If volume retention holds at nine-months, the augmentations can be expected to be permanent. Such results offer women a revolutionary new cosmetic surgery option for smaller volume augmentations, where a more natural look and feel is desired."

At three months, breast circumference in the first three patients remained stable at an average increase of 4 centimeters, which is equivalent to a 1.6 cup size increase. An average net volume of 160mL (less saline) of cell enhanced fat tissue was transplanted into each breast of each patient. The procedure to date has been found safe with no report of any adverse events. Patient follow-up is ongoing in this 20 patient investigator-initiated study. Nine-month results will be reported in early 2009, shortly after the last patient follow-up.

The study is using a procedure whereby a woman's fat tissue is enriched with her own adipose derived stem and regenerative cells to create a natural filler. This technique is referred to as cell-enhanced augmentation. The cells in the study were made available at the time of surgery using the Celution(R) 800 System from Cytori Therapeutics (NASDAQ: CYTX). Further results from the study will be available following a nine month assessment of the primary endpoints of cosmetic improvement and volume retention.

Fat, known medically as adipose tissue, is the body's richest known source of regenerative cells. Adipose-derived regenerative cells include adult stem cells in addition to other important cell types that have been shown pre-clinically to improve tissue retention compared to non- 'cell enhanced' tissue transfers. For this reason, these cells potentially may improve and simplify traditionally complex fat transfer procedures as well as enable more predictable outcomes and graft retention when applied to cosmetic and reconstructive surgery.

Cytori Therapeutics

Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System will be launched in Japan and Asia for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori Therapeutics' Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

SOURCE: Cytori Therapeutics

Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytoritx.com

xxxxxxxxxxxxxxxxxx

2008 ist das Wachstum noch beschränkt aufgrund der Produktionskapazitäten. Für 2009 baut Olympus eine neue Fertigungslinie!

 

aber schon bei Börsenschluss waren unter relativ hohem Volumen Höchstkurse von 6,09 $ erreicht worden. Weiß Jemand was los ist?
Tschau Gretel  

Insgesamt knapp 20 000 Stücke nachbörslich.
Meldung habe ich aber auch keine.

Charttechnisch wäre das natürlich toll!  

erster Kurs bei 6,59 Dollar  

ein Lichtblick....  

47. Ziemlich sichere 15 bis 20% sind drin!   ecki  30.04.08 20:35  

Jetzt schon auf 6,80 USD. Und ausbruch aus der Range mit hohem Volumen.,

Das geht jetzt hoch bis 5,60Euro! ;-)  

 

51. OBV mit sehr starkem Anstieg!

ecki

13.05.08 20:44

 

 

auch wenn der schwache Dollar fast den gesamten Gewinn auffrisst.

Der Chart sieht trotzdem schön aus :-)

Ein USD-Kontokorrentkonto ist gebührenfrei. Dann mußt Du Aktienerlöse nicht in Euro tauschen lassen und kannst das Geld solange in Tagesgeld (z.B. Dynamic Cash - ähnlich der Geldmarktfonds) anlegen, bis Du die nächste Dollar-Anlage tätigst.
Damit schließt Du Kursverluste aus.  

Und wenn ich mir von den Aktiengewinnen nen Kilo Kartoffeln kaufen will?
Irgendwann muss man die Dollars halt doch tauschen.

bis sich der USD wieder gefestigt hat. Prognosen gehen ja von 1,40 per Jahresfrist aus.
(Naja, wer's glaubt).
Aber warten muss man schon können.

obwohl ich mir oft überlegt hatte auszusteigen, habe ich die Aktie doch gehalten und auf einen Anstieg nach der Haltefrist gehofft. Nun scheint es ja tatsächlich wahr zu werden, dass ich ein paar Euro Gewinne mache. Jetzt gleich einen Stopp zu setzen um nicht wieder in die Verlustzone abzudriften dürfe vermutlich Unsinn sein, dann besteht die Gefahr den Anstieg zu verpassen und für die lange Wartezeit entschädigt zu werden.
Tschau Gretel  

empfohlen. Aber keiner der üblichen rein-raus pusher, sondern die haben nur jährlich 10 bis 12 Empfehlungen auf Mehrjahressicht mit mehreren 100% Kurschancen. Wendet sich nur an sehr vermögende Klinientel und kostet jährlich 2000 Dollar oder so.....

Kursziel Cytori soll 32 USD sein. Da kann man ja nur hoffen, das die wirklich etwas langfristiges Kapital mobilisieren. :-)  

9 USD sollten jetzt noch mehr oder weniger in einem Rutsch drinnen sein.....  

 

bis die 9 USD erreicht werden.
und leider führt der folgende Link von
SectorWatch.biz Issues MarketStats on CYTX, HNSN, MDT, SYK, and JNJ
in die Irre, da gehts nicht zu cytori

For more information on Cytori Therapeutics (Nasdaq: CYTX) and this industry visit the following link: http://www.smallcapvoice.com/ctyx/index.php  

http://biz.yahoo.com/bw/080606/20080606005251.html?.v=1

Press Release

Source: Cytori Therapeutics

Cytori and Green Hospital Supply Expand StemSource(R) Cell Bank Commercialization Partnership
Friday June 6, 7:30 am ET

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX - News) and Green Hospital Supply expanded the StemSource® Cell Bank commercialization partnership to include Korea, Taiwan and Thailand. As with the commercialization agreement for Japan, revenues from all related product sales will be shared equally between Cytori and Green Hospital Supply.

“Commercialization activities in Japan have resulted in a significant number of prospective customers not only in Japan, but throughout Asia,” said Seijiro Shirahama, president of Cytori Asia Pacific. “With Green Hospital Supply’s experience and knowledge of the region, we are able to take advantage of the existing product infrastructure to expand the revenue potential for the StemSource® Cell Bank.”

The StemSource® Cell Bank is being commercialized to hospitals in Japan, Korea, Taiwan and Thailand by Green Hospital Supply, Inc., in partnership with Cytori. The foundation of the StemSource® Cell Bank is Cytori's proprietary Celution® 900 System, which automates the separation and concentration of stem and regenerative cells residing within adipose tissue so they may be prepared for cryopreservation.

About Cytori

Cytori’s (NASDAQ:CYTX - News) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution® 900 System will be launched in Japan for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. (www.cytoritx.com)

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori’s Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Contact:

Cytori Therapeutics Tom Baker, 858-875-5258 tbaker@cytoritx.com

---

Source: Cytori Therapeutics

 

...entweder fallen wir heute auf 6 zurück oder steigen auf 11... Bin aber long und verkaufe erst bei 100... irgendwann... 2012?

Ecki, falls ich mich noch nicht bei Dir bedankt habe, so hole ich das hiermit nach. Bin Dir sehr verpflichtet für Deine ausgezeichnete Arbeit! Danke!  

Solche Ansprüche habe ich nicht. Aber ich denke doch, das ein vervielfacher drin ist. Die Marktkap ist immer noch zwergenhaft und Cytori ist vorne dran in einem künftigen Milliardenmarkt.  

da darf man gespannt sein, ob dies im Kurs schon eigepreist ist
Tschau Gretel

Cytori Receives Patent on Core Celution(R) System Technology
- Five Additional Celution(R)-Related Patents Received
Internationally -

SAN DIEGO, Jun 09, 2008 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) received Notification of Issuance from the United States Patent & Trademark Office for its core patent covering the Celution(R) System (USPTO # 7,390,484). This patent protects Cytori's key device technology, which processes adult stem and regenerative cells from adipose tissue at the patient's bedside.

"Cytori pioneered the concept of a bedside device to deliver a patient's own adipose derived stem and regenerative cells in a single procedure," said Marc H. Hedrick, M.D., president of Cytori and named inventor on this patent. "We believe the broad claims in the '484 patent establish a strong barrier-to-entry against potentially competitive cell processing systems and reinforces our leadership position in regenerative medicine."

The new U.S. patent is a central part of Cytori's global patent portfolio, which includes more than 150 pending patent applications and five new previously unannounced international patents. The new patents in Korea and Singapore cover Cytori's current Celution(R) devices. Cytori was also granted patents in Korea and Australia related to the Company's StemSource(R) Cell Bank. In South Africa, Cytori was granted a patent for using adipose derived stem and regenerative cells in cardiovascular cell therapy.

Celution(R) 800 is currently being sold into the reconstructive surgery market and the Celution(R) 900 System is being offered around the globe as part of the Company's StemSource(R) Cell Bank. This patent also covers the Celution(R) family of devices currently in co-development with Cytori's strategic partner, Olympus Corporation.

"The '484 patent is the key foundational patent within our intellectual property portfolio and offers Cytori long-term protection through at least 2024," said Christopher J. Calhoun, chief executive officer of Cytori. "Our patent portfolio works in concert with many other barriers-to-entry to protect all of our target markets for our first-in-class Celution(R) System."

Cytori Therapeutics

Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System will be launched in Japan and Asia for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. (www.cytoritx.com)

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori Therapeutics' Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

SOURCE: Cytori Therapeutics

Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytoritx.com

Copyright Business Wire 2008

News Provided by COMTEX  

vorbörslich schon auf 8.09 USD, allerdings mit kleinen Stückzahlen
Tschau Gretel